Wisconsin health officials have initiated the process to incorporate testing for Krabbe disease into the state’s newborn screening panel. This decision aims to prevent families from experiencing the tragic late diagnosis that led to the death of Collin Cushmann in 2019. Advocates believe that early detection could significantly improve outcomes and protect future infants from this devastating condition.
Regulatory Process and Timeline
The proposal to add Krabbe disease is currently undergoing formal rule-making, as outlined in the Department of Health Services’ documentation. This change is being processed under Chapter DHS 116 as Clearinghouse Rule CR 25-086. The Department has indicated that establishing the necessary laboratory setups and clinical pathways may take several months, potentially extending to two years before testing is fully implemented.
Kirsten Johnson, the Secretary-designee of the Department of Health Services, has confirmed her support for this initiative by signing a letter to include Krabbe on the screening list. The Cushmann family, advocates for this change since 2015, expressed a mix of gratitude and sorrow, as Kevin Cushmann noted, “It’s a little bittersweet, because it’s my last tie to the living Collin.”
The Importance of Early Detection
Krabbe disease is a severe inherited disorder that primarily manifests in infancy, affecting approximately one in 100,000 births, according to the Orphanet Journal of Rare Diseases. The urgency of early intervention is underscored by recent evidence suggesting that the only effective treatment for infantile Krabbe, hematopoietic stem cell transplant, is most beneficial when performed within four to six weeks after birth. This narrow window highlights the critical need for newborn screening and prompt confirmatory testing to ensure timely treatment.
Currently, Wisconsin’s newborn screening program tests for 50 conditions. Once the procedures for Krabbe disease are established, it will become the 51st condition included in the program. Experts recommend a two-tier testing strategy, which starts with a GALC enzyme assay followed by a measurement of psychosine levels. This approach is designed to minimize false positives and ensure that the most urgent cases are identified quickly, as stated in analyses published by ScienceDirect.
Next Steps for Families and Public Participation
Documents related to the proposed rule, including the text and instructions for public commentary, are available on the Department of Health Services’ administrative rules website. This site also provides contact information for the Birth Defect Prevention and Surveillance Program. Parents seeking more information can access fact sheets and FAQs regarding abnormal screening results, the confirmatory testing process, and referral pathways for specialty care.
As Wisconsin moves forward with this important change, the addition of Krabbe disease testing represents a significant step toward enhancing the public health safety net for newborns, potentially saving lives and improving health outcomes for future generations.
